Literature DB >> 26238627

Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?

Sanda Alexandrescu1, Andrey Korshunov2,3, Siang Hui Lai4, Salma Dabiri5, Sushama Patil6, Rong Li7, Chie-Schin Shih8, Jose M Bonnin9, Jonathan A Baker10, Emma Du11, David W Scharnhorst12, David Samuel13, David W Ellison14, Arie Perry1.   

Abstract

Epithelioid glioblastoma (eGBM) and pleomorphic xanthoastrocytoma (PXA) with anaplastically transformed foci (ePXA) show overlapping features. Eleven eGBMs and 5 ePXAs were reviewed and studied immunohistochemically. Fluorescence in situ hybridization for EGFR amplification, PTEN deletion and ODZ3 deletion was also performed, with Ilumina 450 methylome analysis obtained in five cases. The average age for eGBM was 30.9 (range 2-79) years, including five pediatric cases and a M : F ratio of 4.5. The ePXA patients had a M : F ratio of 4 and averaged 21.2 (range 10-38) years in age, including two pediatric cases. Six eGBMs and two ePXAs recurred (median recurrence interval of 12 and 3.3 months, respectively). All tumors were composed of solid sheets of loosely cohesive, "melanoma-like" cells with only limited infiltration. ePXAs showed lower grade foci with classic features of PXA. Both tumor types showed focal expression of epithelial and glial markers, retained INI1 and BRG1 expression, occasional CD34 positivity, and lack of mutant IDH1 (R132H) immunoreactivity. BRAF V600E mutation was present in four eGBMs and four ePXAs. ODZ3 deletion was detected in seven eGBMs and two ePXAs. EGFR amplification was absent. Methylome analysis showed that one ePXA and one eGBM clustered with PXAs, one eGBM clustered with low-grade gliomas, and two eGBMs clustered with pediatric-type glioblastomas. Common histologic, immunohistochemical, molecular and clinical features found in eGBM and ePXA suggest that they are closely related or the same entity. If the latter is true, the nomenclature and WHO grading remains to be resolved.
© 2015 International Society of Neuropathology.

Entities:  

Keywords:  BRAFV600E; ODZ3; epithelioid; glioblastoma; pediatric; pleomorphic; prognosis; xanthoastrocytoma

Mesh:

Substances:

Year:  2015        PMID: 26238627     DOI: 10.1111/bpa.12295

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  30 in total

1.  Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.

Authors:  Rachael A Vaubel; Alissa A Caron; Seiji Yamada; Paul A Decker; Jeanette E Eckel Passow; Fausto J Rodriguez; Amulya A Nageswara Rao; Daniel Lachance; Ian Parney; Robert Jenkins; Caterina Giannini
Journal:  Brain Pathol       Date:  2017-04-02       Impact factor: 6.508

Review 2.  [Alterations in the WHO classification of brain tumors from 2016].

Authors:  W J Schulz-Schaeffer
Journal:  Radiologe       Date:  2017-09       Impact factor: 0.635

3.  Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.

Authors:  Marina Kushnirsky; Lynn G Feun; Sakir H Gultekin; Macarena I de la Fuente
Journal:  JCO Precis Oncol       Date:  2020-02-03

Review 4.  A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Authors:  Martin J van den Bent; Michael Weller; Patrick Y Wen; Johan M Kros; Ken Aldape; Susan Chang
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

5.  The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.

Authors:  Joanna J Phillips; Henry Gong; Katharine Chen; Nancy M Joseph; Jessica van Ziffle; Boris C Bastian; James P Grenert; Cassie N Kline; Sabine Mueller; Anuradha Banerjee; Theodore Nicolaides; Nalin Gupta; Mitchel S Berger; Han S Lee; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Arie Perry; Joseph T C Shieh; David A Solomon
Journal:  Brain Pathol       Date:  2018-11-06       Impact factor: 6.508

Review 6.  Advances in the molecular genetics of gliomas - implications for classification and therapy.

Authors:  Guido Reifenberger; Hans-Georg Wirsching; Christiane B Knobbe-Thomsen; Michael Weller
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

7.  Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma.

Authors:  Kaijun Sun; Xingwang Zhou; Tengfei Li; Mingrong Zuo; Junhong Li; Yanhui Liu
Journal:  Neurosurg Rev       Date:  2021-02-17       Impact factor: 3.042

Review 8.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

9.  Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.

Authors:  Andrey Korshunov; Lukas Chavez; Tanvi Sharma; Marina Ryzhova; Daniel Schrimpf; Damian Stichel; David Capper; Dominik Sturm; Marcel Kool; Antje Habel; Bette K Kleinschmidt-DeMasters; Marc Rosenblum; Oksana Absalyamova; Andrey Golanov; Peter Lichter; Stefan M Pfister; David T W Jones; Arie Perry; Andreas von Deimling
Journal:  Brain Pathol       Date:  2017-10-30       Impact factor: 6.508

Review 10.  Characterization of gliomas: from morphology to molecules.

Authors:  Sean P Ferris; Jeffrey W Hofmann; David A Solomon; Arie Perry
Journal:  Virchows Arch       Date:  2017-07-04       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.